-
EBMT Interview Spotlight | Latest Advances and Challenges in CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia (ALL) is a malignant neoplastic disease that originates from B-cell or T-cell lymphocytes and proliferates abnormally in the bone marrow. In recent years, immunotherapy has made significant strides in the field of ALL, including breakthroughs in treatments such as Chimeric Antigen Receptor T-cell (CAR-T) therapy, bispecific antibodies, and antibody-drug conjugates (ADC). The…
-
EBMT Interview Spotlight | Future Landscape of Multiple Myeloma Treatment: Cell Therapy vs. Transplantation
Multiple myeloma is a clonal plasma cell proliferative disorder that has seen significant therapeutic advancements over the past few decades due to deepening biological research. With the development of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, Chimeric Antigen Receptor T-cell (CAR-T) therapy, and other new drugs, the survival and prognosis for patients with multiple myeloma have…
-
Professor Jun Ma: Fruitful Updates to the 2024 CSCO Lymphoma Treatment Guidelines | 2024 CSCO Guidelines Conference
Lymphoma has become the most prevalent malignant hematological tumor in China. Enhancing the standardized diagnosis and treatment of lymphoma is crucial for improving cure rates. The “Chinese Society of Clinical Oncology (CSCO) Lymphoma Treatment Guidelines” are updated annually and play a significant role in promoting standardized care for lymphoma. At the recent 2024 CSCO Guidelines…
-
Professor Chongjie Pang ‘s Commentary: Can Rapid Antimicrobial Susceptibility Testing Improve Prognosis of Gram-Negative BSI Patients? | ESCMID Global 2024
Bloodstream infection (BSI) is a severe systemic infection, especially with multidrug-resistant bacteria such as carbapenem-resistant Gram-negative organisms (CRO), posing a significant threat to patient safety. Clinical management of BSI faces numerous challenges, with early diagnosis and precise treatment being crucial for improving patient outcomes. At the recent 34th European Congress of Clinical Microbiology and Infectious…
-
Professor YongHong Xiao’s Commentary on Cefiderocol Treatment of Gram-Negative Bacteremia in the GAMECHANGER Study | ESCMID Global 2024
Cefiderocol is a novel siderophore cephalosporin antibiotic with excellent stability against nearly all β-lactamases, including metalloenzymes. It has demonstrated good clinical efficacy against infections caused by carbapenem-resistant Gram-negative bacteria (CRO), garnering significant attention from experts in the field of infectious diseases. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024),…
-
Unveiling Progress in Immunotherapy and Pathological Diagnosis for Urological Cancers: Insights from Dr. Félix Guerrero Ramos and Dr. Xuefeng Qiu at EAU Congress 2024
In a significant gathering at the European Association of Urology (EAU) Congress 2024, held in the vibrant city of Paris, two esteemed figures in the field of urology, Dr. Félix…
-
Professor ChunRong Ju’s Comments: Focus on Long-Term Infections in Solid Organ Transplant Recipients | ESCMID Global 2024
Infection remains a major challenge for recipients of solid organ transplants (SOT), leading to serious risks of mortality and transplant failure. Previous research has primarily focused on the characteristics and prevention of infections within the first year post-surgery, with limited data on long-term infections beyond one year post-surgery. At the recent 34th European Society of…
-
Optimizing Antibiotic Dosage in Obese and Underweight Patients: Insights from Professor Wenxiang Huang ‘s Presentation at ESCMID Global 2024
From April 27th to 30th, 2024, the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024) took place in Barcelona, Spain, known as the “Pearl of the Iberian Peninsula.” ESCMID Global, formerly known as ECCMID, stands as one of the most influential international conferences in the field of infectious diseases. Often, clinical…
Connecting Medical Expertise through Media